NQO1 C609T polymorphism correlated to colon cancer risk in farmers from western region of Inner Mongolia

Chinese Journal of Cancer Research

Volumn 24, Issue 4, 2012, Pages 317-322

  Su, Xiu Lan ^a   Yan, Mei Rong ^a   Yang, Ling ^a   Qimuge Suyila, ^a  

^a INNER MONGOLIA MEDICAL COLLEGE   (China)

Author keywords

Colon cancer; gene polymorphism; Inner Mongolia; NAD(P)H:quinone oxidoreductase 1

Indexed keywords

REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE) 1; UNCLASSIFIED DRUG;

ADULT; AGED; AGRICULTURAL WORKER; ALLELE; ARTICLE; CANCER INCIDENCE; CANCER RISK; CASE CONTROL STUDY; COLON CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; EATING HABIT; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONGOLIA; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 84875477609     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.1007/s11670-012-0270-0     Document Type: Article

References (38)

1. Riley RJ, Workman P. DT-diaphorase and cancer chemotherapy. Biochem Pharmacol 1992;43:1657-1669.
2. Begleiter A, Sivananthan K, Curphey TJ, et al. Induction of NAD(P)H quinone: oxidoreductase1 inhibits carcinogen-induced aberrant crypt foci in colons of Sprague-Dawley rats. Cancer Epidemiol Biomarkers Prev 2003;12:566-572.
3. Begleiter A, Sivananthan K, Lefas GM, et al. Inhibition of colon carcinogenesis by post-initiation induction of NQO1 in Sprague-Dawley rats. Oncol Rep 2009;21:1559-1565.
4. Marín A, López de Cerain A, Hamilton E, et al. DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours. Br J Cancer 1997;76:923-929.
5. Siegel D, Ross D. Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med 2000;29:246-253.
6. Choudry GA, Stewart PA, Double JA, et al. A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9. Br J Cancer 2001;85:1137-1146.
7. Siegel D, Anwar A, Winski SL, et al. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol Pharmacol 2001;59:263-268.
8. Ren JJ, OuYang XH, Su XL. NAD(P)H:quinone oxidoreductase gene polymorphism association with gastric carcinoma. Zhong Hua Zhong liu Fang Zhi Za Zhi (in Chinese) 2006;22:1686-1688.
9. Gervaz P, Bouzourene H, Cerottini JP, et al. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum 2001;44:364-372; discussion 372-3.
10. Kikuchi H, Pino MS, Zeng M, et al. Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer. Cancer Res 2009;69:8499-8506.
11. Lee SH, Lee SJ, Chung JY, et al. p53, secreted by K-Ras-Snail pathway, is endocytosed by K-Ras-mutated cells; implication of target-specific drug delivery and early diagnostic marker. Oncogene 2009;28:2005-2014.
12. Phelps RA, Chidester S, Dehghanizadeh S, et al. A two-step model for colon adenoma initiation and progression caused by APC loss. Cell 2009;137:623-634.
13. Patchett SE, Alstead EM, Saunders BP, et al. Regional proliferative patterns in the colon of patients at risk for hereditary nonpolyposis colorectal cancer. Dis Colon Rectum 1997;40:168-171.
14. Miyakura Y, Sugano K, Akasu T, et al. Extensive but hemiallelic methylation of the hMLH1 promoter region in early-onset sporadic colon cancers with microsatellite instability. Clin Gastroenterol Hepatol 2004;2:147-156.
15. Frattini M, Balestra D, Suardi S, et al. Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res 2004;10:4015-4021.
16. Bian YH, Huang SH, Yang L, et al. Sonic hedgehog-Gli1 pathway in colorectal adenocarcinomas. World J Gastroenterol 2007;13:1659-1665.
17. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981;66:1191-1308.
18. Kim YI, Mason JB. Nutrition chemoprevention of gastrointestinal cancers: a critical review. Nutr Rev 1996;54:259-279.
19. Sarbia M, Bitzer M, Siegel D, et al. Association between NAD(P)H: quinone oxidoreductase 1 (NQ01) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract. Int J Cancer 2003;107:381-386.
20. Zhang J, Schulz WA, Li Y, et al. Association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism with esophageal squamous cell carcinoma in a German Caucasian and a northern Chinese population. Carcinogenesis 2003;24:905-909.
21. Zhang JH, Li Y, Wang R, et al. NQO1 C609T polymorphism associated with esophageal cancer and gastric cardiac carcinoma in North China. World J Gastroenterol 2003;9:1390-1393.
22. Schulz WA, Krummeck A, Rösinger I, et al. Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics 1997;7:235-239.
23. Menzel HJ, Sarmanova J, Soucek P, et al. Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br J Cancer 2004;90:1989-1994.
24. Niwa Y, Hirose K, Nakanishi T, et al. Association of the NAD(P)H: quinone oxidoreductase C609T polymorphism and the risk of cervical cancer in Japanese subjects. Gynecol Oncol 2005;96:423-429.
25. Park SJ, Zhao H, Spitz MR, et al. An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutat Res 2003;536:131-137.
26. Wang YH, Lee YH, Tseng PT, et al. Human NAD(P) H:quinone oxidoreductase 1 (NQO1) and sulfotransferase 1A1 (SULT1A1) polymorphisms and urothelial cancer risk in Taiwan. J Cancer Res Clin Oncol 2008;134:203-209.
27. Hamajima N, Matsuo K, Iwata H, et al. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol 2002;7:103-108.
28. Longuemaux S, Deloménie C, Gallou C, et al. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobioticmetabolizing enzymes. Cancer Res 1999;59:2903-2908.
29. Siegelmann-Danieli N, Buetow KH. Significance of genetic variation at the glutathione S-transferase M1 and NAD(P)H:quinone oxidoreductase 1 detoxification genes in breast cancer development. Oncology 2002;62:39-45.
30. Akkiz H, Bayram S, Bekar A, et al. No association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and risk of hepatocellular carcinoma development in Turkish subjects. Asian Pac J Cancer Prev 2010;11:1051-1058.
31. Begleiter A, Norman A, Leitao D, et al. Role of NQO1 polymorphisms as risk factors for squamous cell carcinoma of the head and neck. Oral Oncol 2005;41:927-933.
32. Kolesar JM, Dahlberg SE, Marsh S, et al. The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. Oncol Rep 2011;25:1765-1772.
33. Lafuente MJ, Casterad X, Trias M, et al. NAD(P) H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. Carcinogenesis 2000;21:1813-1819.
34. Begleiter A, Hewitt D, Maksymiuk AW, et al. A NAD(P) H:quinone oxidoreductase 1 polymorphism is a risk factor for human colon cancer. Cancer Epidemiol Biomarkers Prev 2006;15:2422-2426.
35. van der Logt EM, Bergevoet SM, Roelofs HM, et al. Role of epoxide hydrolase, NAD(P)H:quinone oxidoreductase, cytochrome P450 2E1 or alcohol dehydrogenase genotypes in susceptibility to colorectal cancer. Mutat Res 2006;593:39-49.
36. Qiu XB, Schönthal AH, Cadenas E. Anticancer quinones induce pRb-preventable G2/M cell cycle arrest and apoptosis. Free Radic Biol Med 1998;24:848-854.
37. Xue BJ, Jin ZC. Lochnerol elevates expression of NQO1 and inhibits proliferation of liver cancer cell. Chin J Pathophysiol 2002;18:884-888.
38. Begleiter A, Leith MK, Thliveris JA, et al. Dietary induction of NQO1 increases the antitumour activity of mitomycin C in human colon tumours in vivo. Br J Cancer 2004;91:1624-1631.